BAP1 mutation
|
Mesothelioma
|
BAP1 mutation
|
Mesothelioma
|
tazemetostat Sensitive: C2 – Inclusion Criteria
|
tazemetostat Sensitive: C2 – Inclusion Criteria
|
BAP1 mutation
|
Urothelial Cancer
|
BAP1 mutation
|
Urothelial Cancer
|
olaparib Sensitive: C2 – Inclusion Criteria
|
olaparib Sensitive: C2 – Inclusion Criteria
|
BAP1 mutation
|
Melanoma
|
BAP1 mutation
|
Melanoma
|
vorinostat Sensitive: C2 – Inclusion Criteria
|
vorinostat Sensitive: C2 – Inclusion Criteria
|
BAP1 mutation
|
Mesothelioma
|
BAP1 mutation
|
Mesothelioma
|
olaparib Resistant: C3 – Early Trials
|
olaparib Resistant: C3 – Early Trials
|
BAP1 mutation
|
Cholangiocarcinoma
|
BAP1 mutation
|
Cholangiocarcinoma
|
cisplatin + gemcitabine Resistant: C3 – Early Trials
|
cisplatin + gemcitabine Resistant: C3 – Early Trials
|
BAP1 mutation
|
RCC
|
BAP1 mutation
|
RCC
|
everolimus Resistant: C3 – Early Trials
|
everolimus Resistant: C3 – Early Trials
|
BAP1 mutation
|
RCC
|
BAP1 mutation
|
RCC
|
Tyrosine kinase inhibitor Resistant: C3 – Early Trials
|
Tyrosine kinase inhibitor Resistant: C3 – Early Trials
|
BAP1 mutation
|
Mesothelioma
|
BAP1 mutation
|
Mesothelioma
|
rucaparib Sensitive: C3 – Early Trials
|
rucaparib Sensitive: C3 – Early Trials
|
BAP1 mutation
|
RCC
|
BAP1 mutation
|
RCC
|
Glutamate inhibitor Sensitive: D – Preclinical
|
Glutamate inhibitor Sensitive: D – Preclinical
|
BAP1 mutation
|
Uveal Melanoma
|
BAP1 mutation
|
Uveal Melanoma
|
JNJ 26481585 Sensitive: D – Preclinical
|
JNJ 26481585 Sensitive: D – Preclinical
|
BAP1 mutation
|
Solid Tumor
|
BAP1 mutation
|
Solid Tumor
|
BET inhibitor Sensitive: D – Preclinical
|
BET inhibitor Sensitive: D – Preclinical
|